SCHEMBL424062

SCHEMBL424062

CCBNc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.62

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 15/20 0.62
IKZF3 Q9UKT9 7/20 0.61
IKZF1 Q13422 2/20 0.61
BRD4 O60885 2/20 0.61
DDB1 Q16531 2/20 0.61
TNF P01375 1/20 0.61
IL1B P01584 1/20 0.61
MAP1LC3B Q9GZQ8 3/20 0.55
CSNK1A1 P48729 1/20 0.52
IKZF2 Q9UKS7 1/20 0.49
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425119 0.90 CRBN (0.49) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL17278251 0.86 CRBN (0.66) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL21304411 0.85 CRBN (0.70) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL15711555 0.85 CRBN (0.70) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL21602681 0.84 CRBN (0.64) CRBNIKZF3IKZF1BRD4DDB1
Hydrochloric Acid SCHEMBL1424536 0.84 CRBN (0.69) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL23225993 0.83 CRBN (0.72) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL2383485 0.82 CRBN (0.64) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL29679352 0.82 CRBN (0.64) CRBNIKZF3IKZF1BRD4DDB1
SCHEMBL20993087 0.82 CRBN (0.70) CRBNIKZF3IKZF1BRD4DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140024807-A1 Lenalidomide and Thalidomide Immunoassays SALADAX BIOMEDICAL INC. (US) 2014-01-23 US disclosed
US-20130211052-A1 Lenalidomide and Thalidomide Immunoassays SALADAX BIOMEDICAL INC. (US) 2013-08-15 US disclosed
US-8440796-B2 Lenalidomide and thalidomide immunoassays SALADAX BIOMEDICAL INC. (US) 2013-05-14 US disclosed
US-8293492-B2 Lenalidomide and thalidomide immunoassays SALADAX BIOMEDICAL INC. (US) 2012-10-23 US disclosed
US-20120071632-A1 Lenalidomide and Thalidomide Immunoassays SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2012-03-22 US disclosed
US-20120064549-A1 Lenalidomide and Thalidomide Immunoassays SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2012-03-15 US disclosed
US-8114621-B2 Lenalidomide and thalidomide immunoassays SALADAX BIOMEDICAL INC. (US) 2012-02-14 US disclosed
US-20110223611-A1 LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071632-A1 Lenalidomide and Thalidomide Immunoassays FCGRT, MALT1, SERPINA6 CRBN 26/4885IKZF3 976/4885IKZF1 388/4885
US-20130211052-A1 Lenalidomide and Thalidomide Immunoassays FCGRT, MALT1, SERPINA6 CRBN 26/4885IKZF3 976/4885IKZF1 388/4885
US-20110223611-A1 LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS FCGRT, MALT1, SERPINA6 CRBN 26/4885IKZF3 976/4885IKZF1 388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.